Hoyer Andrew W, Balaji Seshadri
Department of Pediatrics, Division of Pediatric Cardiology, Oregon Health & Science University, Portland, OR 97239, USA.
Pacing Clin Electrophysiol. 2007 Aug;30(8):1003-8. doi: 10.1111/j.1540-8159.2007.00799.x.
The safety and efficacy of ibutilide in the cardioversion of atrial flutter and atrial fibrillation in children and in patients with congenital heart disease (CHD) is unknown.
Data from 19 patients (age 6 months to 34 years, median 16 years) who received ibutilide for atrial flutter or atrial fibrillation between 1996 and 2005 was retrospectively reviewed. There were 15 patients with CHD (14 had prior heart surgery); four children had normal heart structure.
There were 74 episodes of atrial flutter and four episodes of atrial fibrillation (median episodes per patient was one, range 1-31). Ibutilide converted 55 of all the episodes (71%). Ibutilide was successful during its first-ever administration in 12 of 19 patients (63%). Fourteen episodes in six patients required electrical cardioversion after ibutilide failed. There were no episodes of symptomatic bradycardia. One patient went into torsade de pointes and one patient had nonsustained ventricular tachycardia.
With careful monitoring, ibutilide can be an effective tool in selected patients for cardioversion of atrial flutter.
伊布利特用于儿童及先天性心脏病（CHD）患者心房扑动和心房颤动复律的安全性和有效性尚不清楚。
回顾性分析1996年至2005年间19例接受伊布利特治疗心房扑动或心房颤动患者（年龄6个月至34岁，中位年龄16岁）的数据。其中15例为先天性心脏病患者（14例曾接受心脏手术）；4例儿童心脏结构正常。
共发生74次心房扑动发作和4次心房颤动发作（每位患者发作次数中位数为1次，范围1 - 31次）。伊布利特使所有发作中的55次（71%）转复。19例患者中有12例（63%）首次使用伊布利特即成功。6例患者的14次发作在伊布利特治疗失败后需要进行电复律。未出现症状性心动过缓发作。1例患者发生尖端扭转型室速，1例患者出现非持续性室性心动过速。
经过仔细监测，伊布利特可成为部分患者心房扑动复律的有效工具。
